Lilly and Alchemab collaborate on novel therapies for ALS
Eli Lilly and Alchemab Therapeutics hope to discover novel therapeutic candidates to treat amyotrophic lateral sclerosis (ALS) as part of a new research collaboration.
Alchemab’s technology platform uses patient samples from individuals with unusually slow rates of disease progression to identify antibodies associated with resilience.
The company believes these antibodies, which are not found in disease progressors, could present therapeutic opportunities.
Alchemab has acquired hundreds of ALS samples, and this collaboration will leverage Alchemab’s technology to identify antibodies associated with resilience in ALS patient samples and advance the most promising candidates.
Alchemab’s Chief Executive Officer, Jane Osbourn, commented: “We have shown that our novel, differentiated antibody discovery platform can lead to insights into how an individual’s immune response can generate potent, selective, and unique antibodies with therapeutic potential. Guided by patients’ biological response to disease, Alchemab’s platform yields both novel targets and potential therapies in one process.
“ALS is a devastating disease and an area of significant unmet medical need. Our collaboration with Lilly enables us to apply our novel approach to a hugely important disease in partnership with one of the most respected names in pharma. We are looking forward to working together to discover and develop novel targets and therapies for ALS patients.”
Under the terms of the agreement, Alchemab will collaborate with Lilly to discover, develop and commercialise up to five novel therapeutics. Alchemab will receive an undisclosed upfront payment and is eligible to receive discovery, development and commercialisation milestone payments, plus royalties.
Alchemab was founded in 2019 with seed funding from SV Health Investors, DCVC Bio and the Dementia Discovery Fund and has raised in excess of $80 million to date.
Diana Spencer, Senior Digital Content Editor, DDW
